These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 9605174

  • 1. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F.
    J Immunol; 1998 Jun 01; 160(11):5669-75. PubMed ID: 9605174
    [Abstract] [Full Text] [Related]

  • 2. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC.
    Oncol Rep; 2003 Jun 01; 10(1):57-63. PubMed ID: 12469145
    [Abstract] [Full Text] [Related]

  • 3. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
    Michael-Robinson JM, Pandeya N, Cummings MC, Walsh MD, Young JP, Leggett BA, Purdie DM, Jass JR, Radford-Smith GL.
    J Pathol; 2003 Sep 01; 201(1):46-54. PubMed ID: 12950016
    [Abstract] [Full Text] [Related]

  • 4. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
    Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL.
    Clin Cancer Res; 2002 Oct 01; 8(10):3137-45. PubMed ID: 12374681
    [Abstract] [Full Text] [Related]

  • 5. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T, Katayama I, Koji T.
    Mod Pathol; 2002 Apr 01; 15(4):387-96. PubMed ID: 11950912
    [Abstract] [Full Text] [Related]

  • 6. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
    Younes M, Schwartz MR, Ertan A, Finnie D, Younes A.
    Cancer; 2000 Feb 01; 88(3):524-8. PubMed ID: 10649242
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
    Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N.
    Clin Cancer Res; 1999 Sep 01; 5(9):2464-9. PubMed ID: 10499620
    [Abstract] [Full Text] [Related]

  • 8. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U, Gierschner D, Welchner T, Wetterauer U.
    Anticancer Res; 2003 Sep 01; 23(1A):433-7. PubMed ID: 12680244
    [Abstract] [Full Text] [Related]

  • 9. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    Ni X, Hazarika P, Zhang C, Talpur R, Duvic M.
    Clin Cancer Res; 2001 Sep 01; 7(9):2682-92. PubMed ID: 11555580
    [Abstract] [Full Text] [Related]

  • 10. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
    Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T.
    Clin Cancer Res; 2000 Sep 01; 6(9):3560-4. PubMed ID: 10999744
    [Abstract] [Full Text] [Related]

  • 11. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
    Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y.
    Hepatology; 2000 Oct 01; 32(4 Pt 1):761-9. PubMed ID: 11003620
    [Abstract] [Full Text] [Related]

  • 12. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
    O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F.
    J Pathol; 1998 Nov 01; 186(3):240-6. PubMed ID: 10211111
    [Abstract] [Full Text] [Related]

  • 13. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
    Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H.
    Cancer Res; 1998 May 15; 58(10):2057-62. PubMed ID: 9605741
    [Abstract] [Full Text] [Related]

  • 14. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S, Koike N, Adachi S.
    J Cancer Res Clin Oncol; 2002 Feb 15; 128(2):73-9. PubMed ID: 11862476
    [Abstract] [Full Text] [Related]

  • 15. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL.
    Cancer Res; 1999 Oct 15; 59(20):5356-64. PubMed ID: 10537320
    [Abstract] [Full Text] [Related]

  • 16. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
    Satchell AC, Barnetson RS, Halliday GM.
    Br J Dermatol; 2004 Jul 15; 151(1):42-9. PubMed ID: 15270871
    [Abstract] [Full Text] [Related]

  • 17. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE, Shanahan F, O'Connell J, Houston AM.
    Cancer Res; 2005 Nov 01; 65(21):9817-23. PubMed ID: 16267003
    [Abstract] [Full Text] [Related]

  • 18. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
    Houston A, Waldron-Lynch FD, Bennett MW, Roche D, O'Sullivan GC, Shanahan F, O'Connell J.
    Int J Cancer; 2003 Nov 01; 107(2):209-14. PubMed ID: 12949796
    [Abstract] [Full Text] [Related]

  • 19. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas.
    Kase S, Osaki M, Adachi H, Kaibara N, Ito H.
    Int J Oncol; 2002 Feb 01; 20(2):291-7. PubMed ID: 11788891
    [Abstract] [Full Text] [Related]

  • 20. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K.
    Int J Oncol; 2001 Jan 01; 18(1):33-9. PubMed ID: 11115536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.